Примери за използване на Disease recurrence на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Disease recurrence can be prevented.
Suitable for prevention of disease recurrence.
Emerging risk factors and disease recurrence represent continued challenges in the management of CDI.
Observing a sparing diet in chronic pancreatitis reduces the risk of disease recurrence.
Otherwise, the risk of heart disease recurrence is quite high.
Хората също превеждат
For the HiLo study, 434(99%)of the original 438 patients were followed up for disease recurrence.
For the adjuvant treatment of melanoma,KEYTRUDA should be administered until disease recurrence, unacceptable toxicity, or for a duration of up to one year.
For the ESTIMABL1 study, 726(97%)of the original 752 patients were followed up for disease recurrence.
The prognosis for disease recurrence is based on general statistics, according to which about 15% of relapses occur more than five years after the removal of the tumor.
It has been observed that this treatment reduces disease recurrence and prolongs survival.
Many health practitioners consider diet as one of the most helpful factors which can eliminate the possibility of disease recurrence.
There may also be biologic factors contributing to a higher risk of disease recurrence for younger women with breast cancer.
After disappear visible signs of onychomycosis,the drug should be continued for a further 14 days to avoid re-infection and disease recurrence.
During the 31 months of follow up, the US researchers recorded 117 events,including disease recurrence, bone tumours and deaths specifically caused by prostate cancer.
If during the treatment of hemorrhoids and constipation left unattended,the high risk of disease recurrence.
Patients with EBC should be treated with Herzuma for 1 year or until disease recurrence, whichever occurs first; extending treatment in EBC beyond one year is not recommended(see section 5.1).
This will play a role in prescribing treatment and in preventing future disease recurrence.
Two Phase 3 clinical studies were completed in a total of 851 postmenopausal women with advanced breast cancer who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease. .
Patients with early breast cancer should be treated for 1 year or until disease recurrence.
In the adjuvant setting, Perjeta should be administered in combination with trastuzumab for a total of one year(up to 18 cycles or until disease recurrence, or unmanageable toxicity, whichever occurs first) as part of a complete regimen for early breast cancer and regardless of the timing of surgery.
Conscious involvement of the patient in collaboration with a doctor ora psychologist is also important in prevention of disease recurrence.
Uncommon infusion related reaction*, irritability, fibrosis,inflammation, disease recurrence, feeling hot, ulcer.
Selection of drugs depends on the site of inflammation, symptoms of the disease andwill be directed to the prevention of disease recurrence.
Patients should receive treatment for a total of 14 cycles unless there is disease recurrence or unmanageable toxicity.
For the primary endpoint, DFS,the addition of trastuzumab to paclitaxel chemotherapy resulted in a 52% decrease in the risk of disease recurrence.
The primary analysis of the study after 2 years post-randomisation demonstrated that Nerlynx significantly reduced the risk of invasive disease recurrence or death by 34%(HR=0.66 with 95% CI(0.49, 0.90), two-sided p= 0.008) in the ITT population.
Herceptin in the control arm,the addition of Herceptin to paclitaxel chemotherapy resulted in a 52% decrease in the risk of disease recurrence.
They are more likely to end up in the hospital,experience treatment delays and disease recurrence; and are less likely to survive.
Despite the cross-over to trastuzumab in the control arm,the addition of trastuzumab to paclitaxel chemotherapy resulted in a 52% decrease in the risk of disease recurrence.
Clinical safety andefficacy in advanced breast cancer Two phase III clinical trials were completed in a total of 851 postmenopausal women with advanced breast cancer who had disease recurrence on or after adjuvant endocrine therapy or progression following endocrine therapy for advanced disease. .